A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Active Targeted Immunotherapy CV-MG01 in Patients With Moderate to Severe Myasthenia Gravis.

Trial Profile

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Active Targeted Immunotherapy CV-MG01 in Patients With Moderate to Severe Myasthenia Gravis.

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs CV MG01 (Primary)
  • Indications Myasthenia gravis
  • Focus Therapeutic Use
  • Sponsors CuraVac
  • Most Recent Events

    • 17 Nov 2017 Planned initiation date changed from 16 Jun 2017 to 1 Jan 2018.
    • 17 Nov 2017 Status changed from recruiting to not yet recruiting.
    • 20 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top